基本信息
views: 276
Career Trajectory
Bio
Dr. Fisher’s cancer research focuses on the daunting challenge facing clinicians and cancer patients, namely identifying, treating and monitoring cancers once they have metastasized from the primary tumor. His efforts have led to development of novel technologies that simultaneously detect and diagnose tumors as well as effectively treat them – or a theranostic approach. With NFCR funding since 2008, Dr. Fisher is now developing an immunotheranostic by genetically engineering a tumor suppressor previously discovered by him to produce a fluorescent (light) signal, allowing for diagnosis, treatment and monitoring of tumors. The fluorescent signal can be imaged using current non-invasive imaging techniques to detect the precise location of metastatic cells and monitor the tumor size after treatment.
NFCR funding has allowed Dr. Fisher to successfully incorporate the tumor suppressing immuno-theranostic into an ‘adoptive cell therapy’ to reduce prostate tumors in mice. In the laboratory, his adoptive therapy first collects the immune T cells from mice to genetically modify the cells with anticancer genes he discovered. After reinjection, the supercharged T cells seek out and deliver an immune enhancer gene that kills any prostate cancer cells. His therapy also provides an imaging tool to identify all metastases and monitor destruction of the tumor using non-invasive imaging. Dr. Fisher’s immuno-theranostic therapy could effectively treat not only metastatic prostate cancer but has the potential to treat virtually any solid tumor, and with modifications, blood cancers.
NFCR funding has allowed Dr. Fisher to successfully incorporate the tumor suppressing immuno-theranostic into an ‘adoptive cell therapy’ to reduce prostate tumors in mice. In the laboratory, his adoptive therapy first collects the immune T cells from mice to genetically modify the cells with anticancer genes he discovered. After reinjection, the supercharged T cells seek out and deliver an immune enhancer gene that kills any prostate cancer cells. His therapy also provides an imaging tool to identify all metastases and monitor destruction of the tumor using non-invasive imaging. Dr. Fisher’s immuno-theranostic therapy could effectively treat not only metastatic prostate cancer but has the potential to treat virtually any solid tumor, and with modifications, blood cancers.
Research Interests
Papers共 977 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Advanced Sensor Researchno. 6 (2024): n/a-n/a
Advances in Cancer Research (2024)
Jessanne Y Lichtenberg, Ella Ramamurthy, Anna D Young, Trey P Redman, Corinne E Leonard,Swadesh K Das,Paul B Fisher,Christopher A Lemmon,Priscilla Y Hwang
PLoS ONEno. 1 (2024): e0296153-e0296153
Methods in molecular biology (Clifton, N.J.) (2024): 1-20
Journal of experimental zoology. Part A, Ecological and integrative physiology (2024)
Jordan R Hansford, Gauthier Bouche,Vijay Ramaswamy,Nada Jabado, Adriana Fonseca, Sam Moloney,Nicholas G Gottardo, Giles W Robinson,Amar Gajjar, Christopher L Tinkle,Paul G Fisher, Nicholas Foreman,
Journal of clinical oncology : official journal of the American Society of Clinical Oncologypp.JCO2400709-JCO2400709, (2024)
Michelle Monje,Jasia Mahdi,Robbie Majzner,Kristen Yeom,Liora M Schultz,Rebecca M Richards,Valentin Barsan,Kun-Wei Song, Jen Kamens,Christina Baggott,Michael Kunicki, Alexandria Sung Lim,
medRxiv the preprint server for health sciences (2024)
crossref(2023)
Load More
Author Statistics
#Papers: 979
#Citation: 41145
H-Index: 102
G-Index: 160
Sociability: 8
Diversity: 3
Activity: 140
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn